Charles River Laboratories International, Inc. CRL

Full chart Compare
Set alert

Price alert · CRL

All alert types
351.87 USD +13.33 (+3.94%)

At closeNov 3, 2026, 6:00 PM EST

351.00 -0.87 -0.25%

After hours · Nov 3, 6:00 PM ET

339.00 Day range 356.35
146.20 52-week range 379.63
YTD
+76.39%
1 year
+96.73%
Market cap
16.95B
Revenue (ttm)
4.00B
Profit margin
-5.96%
EPS (ttm)
-4.80
Shares out
47.74M
Forward P/E
27.61
YTD return
+76.39%
1-year return
+96.73%
Volume
1.51M
Avg volume
1.05M
Open
339.88
Previous close
338.54
Day's range
339.00 – 356.35
52-week range
146.20 – 379.63
Beta
1.34
Analysts
Buy
Price target
318.87 (-9.4%)
Earnings date
Nov 4, 2026

6M +179.55 (+104.20%)

200300May 21Jun 29Aug 5Sep 10Oct 15351.87

Key statistics

Enterprise value
19.05B
PEG ratio
0.12
Price / sales
4.20
Price / book
5.91
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
-2.70%
Free cash flow
468.86M
Total cash
192.02M
Total debt
3.03B
Return on equity
-7.52%
Short % of float
6.86%
50-day average
302.78
200-day average
222.36

Financials — quick view

All financials
CRL Revenue — quarterly 1.00B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CRL Net income — quarterly -1.48M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CRL EPS — quarterly -0.03
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

CRL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 27, 20262.97———
Aug 5, 2026Jun 27, 20262.743.02+0.28+10.22%
May 7, 2026Mar 28, 20261.962.06+0.10+5.10%
Feb 18, 2026Dec 27, 20252.332.39+0.06+2.58%
Nov 5, 2025Sep 27, 20252.322.43+0.11+4.74%
Aug 6, 2025Jun 28, 20252.503.12+0.62+24.80%

Upgrades / downgrades

CRL analyst upgrades and downgrades
DateFirmActionFromTo
Oct 13, 2026Morgan StanleymainOverweightOverweight
Sep 28, 2026JefferiesmainBuyBuy
Sep 25, 2026Deutsche BankmainBuyBuy
Sep 25, 2026TD CowenmainBuyBuy
Sep 25, 2026Evercore ISI GroupmainOutperformOutperform
Sep 25, 2026RBC CapitalmainOutperformOutperform

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
criver.com

News

Your note

Sign in to keep a note on CRL — it syncs with the Stock Master app.

Insider holders

CRL insider holders
InsiderRelationLatest transactionDateShares held
BARBO WILLIAM DOfficerStock GiftNov 6, 20240
COLEMAN GLENN GChief Financial OfficerStock Award(Grant)May 28, 202627,752
CREAMER VICTORIA LOfficerSaleAug 5, 202630,051
FOSTER JAMES CDirectorSaleOct 21, 2026233,410
GIRSHICK BIRGITChief Executive OfficerStock GiftAug 18, 202679,288
LAPLUME JOSEPH WOfficerStock GiftAug 9, 202631,041

Institution ownership

CRL institution ownership
Holder% heldSharesValueReported
FMR, LLC8.88%4,239,7521.49BJun 29, 2026
Blackrock Inc.7.96%3,798,5601.34BJun 29, 2026
Vanguard Capital Management LLC6.60%3,149,2881.11BJun 29, 2026
Invesco Ltd.6.25%2,984,7851.05BJun 29, 2026
Harris Associates L.P.4.69%2,241,144788.59MJun 29, 2026
Vanguard Portfolio Management LLC4.63%2,210,979777.98MJun 29, 2026

Fund ownership

CRL fund ownership
Holder% heldSharesValueReported
Fidelity Contrafund3.82%1,825,159642.22MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.21%1,530,171538.42MJun 29, 2026
HARRIS ASSOCIATES INVESTMENT TRUST-Oakmark Select Fund3.14%1,498,000527.10MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.61%1,247,732439.04MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.31%1,104,850388.76MJun 29, 2026
ALLSPRING FUNDS TRUST-Allspring Special Mid Cap Value Fund1.64%784,906276.18MAug 30, 2026